Researchers Discover a Plant-Based Compound That Cuts Off Leukemia’s Fuel Supply

Acute myeloid leukemia (AML) is an aggressive blood cancer that is notoriously difficult to treat, often returning even after grueling rounds of traditional chemotherapy. As medical researchers look beyond conventional, highly toxic treatments, they are increasingly focusing on the fundamental biology of how these cancer cells survive and sustain their rapid growth.

A recent breakthrough from the University of Guelph has identified a unique metabolic vulnerability in AML cells: a strict, inflexible dependence on fat for energy.

The Critical Vulnerability of Leukemia Cells

At a fundamental level, every cell requires a reliable energy source to survive. Healthy cells operate with remarkable flexibility, easily switching between different fuel options such as fats or sugars depending on what is readily available in the body.

Recent research published in the hematology journal Blood reveals that acute myeloid leukemia (AML) cells completely lack this adaptability. A research team led by Dr. Paul Spagnuolo in the Department of Food Science at the University of Guelph discovered that these aggressive cancer cells are metabolically inflexible. Instead of alternating fuel sources, AML cells rely almost entirely on breaking down specific long-chain fatty acids to sustain their rapid growth.

This rigid dependence on a single energy pathway creates a critical vulnerability. Dr. Spagnuolo illustrates this limitation clearly. “Think of it like a fuel system,” he notes. “Healthy cells are hybrid cars that can switch energy sources. Leukemia cells, on the other hand, are locked into one fuel type to survive.”

Because these cancer cells cannot pivot to alternative energy pathways like healthy cells can, cutting off their preferred fat supply presents a unique opportunity. This metabolic flaw establishes the groundwork for a highly targeted treatment strategy that aims to starve the disease without harming the rest of the body.

Starving Leukemia’s Fuel Line

Understanding the metabolic limits of leukemia cells was only the first phase of the puzzle. The next challenge was finding a mechanism to exploit this weakness safely. The research team zeroed in on a specific protein called ABCD1. This protein functions as a cellular gatekeeper, controlling the entry of long-chain fatty acids into the cell’s processing centers. The researchers noted that acute myeloid leukemia cells produce this protein at significantly higher levels than normal blood cells do.

To stop this fat-to-fuel conversion, the team developed a novel compound derived from jojoba. While this plant is native to the Sonoran Desert and most famous for its use in cosmetic skincare, its chemical properties presented a unique medical opportunity.

When applied in the laboratory, the jojoba-derived compound successfully jammed the ABCD1 gate. This action effectively starved the leukemia cells of their required energy.

Dr. Spagnuolo clarifies exactly how this biological reaction unfolds. “When we inhibited the ABCD1 protein, the leukemia cells could no longer process the fats they depend on,” he states. “The fats built up inside the cells, ultimately causing the cancer cells to die.”

Because healthy blood cells retain their natural adaptability, they simply activated alternative metabolic pathways and continued to thrive. This type of selective toxicity represents the ideal outcome in oncology research, as it actively destroys the disease while leaving healthy tissue completely unharmed.

Advancing Beyond Traditional Chemotherapy

While standard chemotherapy remains the primary defense against acute myeloid leukemia, it frequently leaves behind microscopic traces of the disease. These remaining leukemia stem cells are notoriously resilient and often cause the cancer to return. Traditional treatments function by attacking rapidly dividing cells indiscriminately, resulting in severe side effects and physical exhaustion for patients.

The jojoba-derived compound offers a highly specific alternative that addresses this precise gap in current medical protocols. By targeting the metabolic engine of the cancer rather than just its reproductive cycle, the newly discovered compound demonstrates an ability to dismantle the exact cells that typically evade standard chemotherapy drugs.

In preclinical laboratory models, disrupting the fat-processing abilities of leukemia cells yielded significant results. The intervention prevented the cancer cells from adapting and surviving. Researchers observed that when the acute myeloid leukemia cells lost their primary energy source, they became significantly weaker. This metabolic starvation could potentially make the remaining cancer cells much more susceptible to lower, safer doses of traditional medical interventions.

The Path from Laboratory to Clinical Application

Translating a botanical discovery into a viable oncology treatment requires transforming a raw compound into a standardized, clinical-grade drug. While the jojoba-derived compound successfully disrupted the ABCD1 protein in isolated cellular models, laboratory efficacy is only the preliminary step in pharmaceutical development.

The immediate scientific hurdle is pharmacokinetics—the study of how the body absorbs, distributes, and metabolizes a drug. To be effective against acute myeloid leukemia, the synthesized compound must safely navigate the human bloodstream and successfully penetrate the bone marrow, where leukemia originates and resides. Additionally, researchers must refine the molecule to ensure chemical stability so that it can be consistently manufactured with precise, uniform dosing.

Before this metabolic inhibitor can be integrated into patient care, it must pass rigorous clinical trials. These mandatory human studies are designed to establish strict safety parameters, identify the maximum tolerable dose, and monitor for potential adverse interactions with existing chemotherapy protocols. Most importantly, these trials will definitively test whether the targeted cellular starvation observed in the laboratory successfully translates into measurable, sustained remission for patients.

Precision Over Brute Force

Treating aggressive blood cancers has relied on a strategy of brute force—overwhelming the body with toxic chemotherapy in hopes of destroying the disease before the physical toll becomes intolerable. The discovery by the University of Guelph regarding acute myeloid leukemia and its vulnerability to a jojoba-derived compound represents a crucial shift in this medical paradigm. By mapping and exploiting the exact metabolic dependencies of cancer cells, researchers are demonstrating that outsmarting the disease is a far more sustainable approach than simply overpowering it.

This development underscores the critical need for continued investment at the intersection of botanical pharmacology and metabolic oncology. The natural world continues to hold highly specific chemical keys to complex biological locks, but translating these botanical mechanisms into viable treatments requires sustained institutional funding and rigorous scientific investigation.

While immediate clinical availability remains on the horizon, the successful inhibition of the ABCD1 protein provides a clear, scientifically grounded blueprint for the future of cancer care. Patient advocacy groups, medical professionals, and families affected by leukemia can actively support this evolving frontier by championing cancer metabolism research and closely monitoring the progress of metabolic inhibitors as they advance toward clinical trials. Targeting a cancer’s energy supply is no longer just a theoretical concept; it is actively shaping the next generation of life-saving therapeutics.

Source:

1. Ekaterina N. Parfenova, Nikolina Vrdoljak, Drake A. Mosca, Juan J. Aristizabal-Henao, Michael A. Kiebish, Mark D. Minden, Paul A. Spagnuolo, Targeting ABCD1 inhibits peroxisomal fatty acid oxidation to selectively eliminate acute myeloid leukemia cells, Blood, Volume 147, Issue 24, 2026, Pages 2930-2943, ISSN 0006-4971, https://doi.org/10.1182/blood.2025031202.